Jump to start of content

Complete requirements by 12/31/18 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/18 could result in a change to your certification status.

Breadcrumb trail:

Hematology Board Exam Committee

Expand All | Collapse All

Anne T. Neff, MD, Chair

Dr. Neff is currently a staff physician in Benign Hematology at the Cleveland Clinic Hospitals' Department of Hematology/Medical Oncology. She is board certified in Internal Medicine, Hematology, Blood Banking and Transfusion Medicine.

Previously, Dr. Neff was a Professor of Medicine, Pathology, Microbiology and Immunology at Vanderbilt University. There she also served as Director of the Hemostasis & Thrombosis Clinic, Director of Transfusion Medicine and was the founding Director of the stem cell collection program.

Dr. Neff has served on national committees for the American Association of Blood Banks including Chair of the Scientific Section of the Annual Program Planning committee, Standards Committee for Blood Banks and Transfusion Services, and Standards for Cellular Therapy Products. She has served on the American Society of Hematology's (ASH) Transfusion Scientific Committee and as a speaker at the Highlights of ASH programs in 2014. She was elected to serve on the Board of Directors for the Hemophilia and Thrombosis Research Society from 2008 to 2011. Additionally, Dr. Neff is Chair of the American Board of Internal Medicine Hematology Board Exam Committee.

Dr. Neff earned her bachelor's degree in psychology at the University of Missouri-Columbia, where she also graduated with her medical degree and trained in internal medicine. She did her fellowship training in hematology at Vanderbilt University.

As of January 2017, Dr. Neff reported the following external relationships:

Funding for clinical trial staff, paid to the Cleveland Clinic Foundation, from the following companies:

  • Shire Pharmaceuticals, for a registry of patients with acquired hemophilia who receives recombinant porcine factor VIII.

Service on data and safety monitoring boards for the following company, with compensation as listed:

  • Pfizer, for a recombinant FXa Phase I trial in bleeding disorder patients, receiving an hourly rate for work performed.
  • American Thrombosis and Hemostasis Network, for staff and salary support from, paid to Cleveland Clinic Foundation, to collate data for epidemiologic studies.

Kristie A. Blum, MD

Dr. Blum is an Associate Professor in the Division of Hematology and Section Head of the Lymphoma Program at The Ohio State University. She is board certified in Hematology and Medical Oncology with expertise and extensive experience in the clinical development of novel therapeutics for patients with aggressive B-cell non-Hodgkin (NHL) and Hodgkin's lymphoma (HL).

Dr. Blum has been a faculty member at The Ohio State University since 2003, as an Associate Professor from 2010 to 2015 and as an Assistant Professor from 2003 to 2010.

Dr. Blum was the Associate Director of the Hematology/Oncology Fellowship Program from 2005-2008 and the Director of the Hematology/Oncology Fellowship from 2008-2013. Stepping down from her fellowship role, she led The Ohio State University Lymphoma Clinical and Research Programs in 2013. Dr. Blum also serves on the American Board of Internal Medicine Hematology Board Exam Committee, the Lymphoma Research Foundation Scientific Advisory Board, the Alliance Co-Operative Group Lymphoma Committee, the American Society of Hematology Clinical Research Mentoring Program, and the National Comprehensive Cancer Network Hodgkin's Lymphoma Panel. She has directed and chaired the first Lymphoma Research Foundation Clinical Research Mentoring Program.

Dr. Blum has experience in the design, conduct and publication of phase I-II trials, with focused interest in drug development in lymphomas. She has been involved in several high-impact pharmaceutical trials including trials with lenalidomide, ibrutinib, brentuximab and idelalisib that have led to FDA approvals of several of these agents.

Dr. Blum earned her medical degree at the University of Miami. She completed internal medicine residency from 1997 to 2000 at University of Virginia, her hematology/oncology fellowship training at Vanderbilt University from 2000 to 2001 and Washington University in St. Louis from 2001 to 2003.

As of January 2017, Dr. Blum reported the following external relationships:

Funding for clinical trial expenses and staff, paid to The Ohio State University, from the following companies:

  • Cephalon, for a Phase ½ study of gemcitabine and bendamustine in patients with Hodgkin lymphoma.
  • MorphoSys, for a trial of anti-CD19 antibody in relapsed non-Hodgkin lymphoma patients.

Funding for clinical trial expenses, staff and salary support, paid to The Ohio State University, from the following companies:

  • Celgene, for trials of lenalidomide in patients with non-Hodgkin lymphoma and Hodgkin lymphoma.
  • Morphosys, for a trial of anti-CD19 antibody in patients with relapsed non-Hodgkin lymphoma.
  • Seattle Genetics, for trials of brentuximab in relapsed and upfront Hodkin lymphoma, and of SGN-40 in non-Hodgkin lymphoma.
  • Pharmacyclics, for trials of ibrutinib and R-bendamustine in relapsed lymphoma.
  • Novartis, for trials of MCL-1 inhibitor in relapsed lymphoma.

Dr. Blum serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Alliance for Clinical Trials in Oncology, Alliance Lymphoma Committee, Cadre Member, receiving reimbursement for travel expenses.
  • Lymphoma Research Foundation, Scientific Advisory Board; LRF Clinical Research Mentoring Program, Chair, receiving reimbursement for travel expenses.

Kelly M. Davidson, MD

Dr. Davidson is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of Virginia (UVA), where she practices hematology at the Emily Couric Clinical Cancer Center. She was initially certified in internal medicine, medical oncology and hematology, and maintains her certification in hematology.

Dr. Davidson specializes in a variety of benign and malignant hematologic diseases, with a focus on cellular hematology. She sees patients with myeloproliferative and myelodysplastic disorders, red cell disorders including sickle cell disease, bone marrow failure syndromes, plasma cell dyscrasias, mast cell disorders and disorders of hemostasis and thrombosis. In addition to clinical practice, Dr. Davidson teaches in the second-year medical student course in hematology and plays an active role in resident and fellowship training at UVA. She previously practiced both hematology and oncology at Associates in Oncology/Hematology in Rockville, Maryland.

From 2015 through present, Dr. Davidson has been named to the list of Best Doctors in America. In 2016, she served on the American Board of Internal Medicine (ABIM) Standard Setting Panel for the Hematology Maintenance of Certification Exam (ABIM), and currently serves as a member of the ABIM Hematology Board Exam Committee. She has been a member of the American Society of Hematology since 2003.

Dr. Davidson received a biology degree summa cum laude from Georgetown University and her medical degree from Washington University in St. Louis. She completed internship and residency in internal medicine at Beth Israel Deaconess Medical Center in Boston and fellowship training in hematology and oncology at UVA.

As of July 2018, Dr. Davidson reported no external relationships.

Chancellor E. Donald, MD

Dr. Donald currently practices at Lourdes Oncology Associates in Lafayette, Louisiana. In 2010, he joined the practice and became Managing Partner in 2014. Additionally, at Our Lady of Lourdes Regional Medical Center, he functions as Medical Director of the oncology service line, a member of the Medical Executive Committee and as a Trustee on the Board of Directors.

Dr. Donald is board certified in Internal Medicine, Hematology and Medical Oncology. He serves on the American Board of Internal Medicine’s Hematology Exam Board Committee.

Dr. Donald advocates for patients with malignancies and hematologic disorders. He is currently President of the Louisiana Oncology Society. He has been appointed to the Board of Directors of the Community Oncology Alliance. In 2013, he was given the Spirit of Hope Award by the American Cancer Society. The American Society of Hematology (ASH) selected him for its Committee on Practice. He also holds the position of ASH’s alternate delegate to the American Medical Association’s House of Delegates. Since 2012, he has served as the Hematology Representative for Louisiana for the Medicare Carrier Advisory Committee (CAC). He served as co-chair of the 2017 annual CAC meeting at the American Society of Clinical Oncology headquarters and was again selected for that role for the 2018 annual meeting at the American Society of Hematology headquarters. For the 2017 Annual Meeting of the American Society of Hematology, he served as the clinical designee to the Program Committee.

Dr. Donald graduated magna cum laude from Florida A&M University and received his medical degree from the University of Miami School of Medicine. He completed his internship, residency and fellowship at Tulane University. He served as Chief Resident and Chief Fellow there and currently holds the position of Clinical Assistant Professor within Tulane’s Department of Hematology/Oncology.

As of July 2018, Dr. Donald reported the following external relationships:

Dr. Donald serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Standing Member of Committee on Practice; Alternate Delegate to the House of Delegates of the American Medical Association; receiving reimbursement for travel expenses.
  • Community Oncology Alliance, Board of Directors, Member, without compensation.
  • Our Lady of Lourdes Regional Medical Center, Board of Directors, Member; Medical Executive Committee, Member; and Medical Director of the Oncology Service Line, receiving per diem for attending board meetings.
  • Louisiana Oncology Society, Board of Directors, Member, without compensation.

Morie A. Gertz, MD

Dr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair of the Department of Medicine at the Mayo Clinic. He is board certified in Internal Medicine, Hematology and Medical Oncology.

Previously, Dr. Gertz served as Treasurer for the International Myeloma Society and as President of Mayo Staff Officers and Councilors. He was the Chair of the Mayo Personnel Committee. He currently serves on the American Society of Hematology Training Program Committee and the American Board of Internal Medicine Hematology Board Exam Committee.

He has been recognized with the 2014 Jan Waldenström Medal for Medical and Scientific Achievements in Waldenström's Macroglobulinemia and is a Mayo Distinguished Clinician. He has been recognized for his contributions in amyloidosis and Waldenström's macroglobulinemia. He has authored more than 500 peer-reviewed publications in the field and is a frequently invited speaker nationally.

Dr. Gertz is a master of the American College of Physicians. His undergraduate degree was awarded with highest distinction from Northwestern University, graduating Phi Beta Kappa. He received his medical degree cum laude from Loyola Medical School and was elected to Alpha Omega Alpha, the medical honor society. He completed a three-year medical residency at Rush Presbyterian St. Luke's Hospital in Chicago and was voted Resident of the Year for two of those years.

As of January 2017, Dr. Gertz reported the following external relationships:

Preclinical research, with funding for staff provided to the Mayo Clinic, from the following company:

  • Annexon Biosciences, for patient sera for antibody testing.

Funding for clinical trial expenses and staff, from the following companies:

  • Alnylam, for a trial of imRNA for familial amyloidosis, providing funding for staff, paid to Mayo Clinic.
  • Isis Pharmaceuticals, for a trial of IRNA for familial amyloidosis, providing funding for staff and expenses.
  • Millennium for a trial of bortezomib for amyloidosis AL, providing funding for staff, paid to Mayo Clinic.
  • Pfizer Pharmaceuticals, for a trial of tafamidis for cardiac amyloidosis, providing funding for staff, paid to Mayo Clinic.

Attendance at investigators' meetings, with compensation as listed from the following companies:

  • Millennium, to discuss a strategic planning model, receiving reimbursement for travel expenses and honoraria.
  • Novartis, for sales force education, receiving reimbursement for travel expenses and honoraria.

Service on data and safety monitoring boards for the following company, with honoraria:

  • AbbVie, for a Phase III trial of venetoclax.

Service on research-related expert panel or advisory board for the following company, with compensation as listed:

  • Celgene, to advise on medical content of lectures sponsored by the company, receiving reimbursement for travel expenses and honoraria.

Industry-supported continuing medical education supported by the following, with compensation as listed:

  • Onyx, receiving reimbursement for travel expenses and honoraria.

Teaching in industry-sponsored satellite symposia with funding from the following company, with compensation as

  • Research to Practice, a medical education company that receives support from pharmaceutical companies, receiving reimbursement for travel expenses and honoraria.

Work as an author or editor for following company, with compensation as listed:

  • BMJ Point of Care, receiving compensation for creating online content.

Dr. Gertz serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Training Committee, receiving reimbursement for travel expenses.
  • Amyloidosis Support Network, receiving reimbursement for travel and other expenses associated with providing lectures to patients.
  • International Waldenstroms Macroglobulinemia Foundation receiving reimbursement for travel and other expenses associated with providing lectures to patients.

Cindy A. Leissinger, MD

Dr. Leissinger is Professor of Medicine and Clinical Professor of Pediatrics and Pathology at Tulane University in New Orleans, Louisiana, and is Chief of the Hematology/Oncology Division there. She became Director of the Louisiana Comprehensive Hemophilia Care Center (now the Louisiana Center for Bleeding and Clotting Disorders) in 1992, and has remained in that position ever since. She is board certified in Internal Medicine and Hematology.

In addition to caring for patients with bleeding and clotting disorders, Dr. Leissinger oversees an active research program. She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.

Dr. Leissinger is a member of the American Board of Internal Medicine Hematology Board Exam Committee. Additionally, she is actively involved in the American Society of Hematology, the International Society on Thrombosis and Haemostasis, and the Hemostasis and Thrombosis Research Society.

Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at the National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.

As of January 2017, Dr. Leissinger reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Tulane University, from the following companies:

  • CSL Behring, for a study of a new FVIII product.
  • Roche, for a study of a new Factor VIII mimetic protein.

Dr. Leissinger serves in a significant role with the following organization:

  • Hemostasis and Thrombosis Research Society, President-Elect, receiving no compensation.

Robert T. Means Jr., MD

Dr. Means, a board certified internist and hematologist, is Dean and Professor of Internal Medicine at the James H. Quillen College of Medicine, East Tennessee State University in Johnson City, Tennessee.

Before coming to Quillen, he was Executive Dean of the University of Kentucky College of Medicine. Other positions Dr. Means held at Kentucky included Senior Associate Chair of Internal Medicine, Interim Director of the Markey Cancer Center and Chief of the Medical Service at the Lexington VA Medical Center. He served as Director of the Hematology Oncology Division at the Medical University of South Carolina, and was on faculty at the University of Cincinnati and Vanderbilt.

Dr. Means is a member of the American Board of Internal Medicine Hematology Board Exam Committee. He is past President of the Southern Society for Clinical Investigation and a Fellow of the American College of Physicians. He is also an Associate Editor of the Journal of Investigative Medicine, and serves on editorial boards for the American Journal of the Medical Sciences, Blood Research, and International Journal of Hematology. He is on the Medical & Scientific Advisory Board of the Iron Disorders Institute.

Dr. Means received his bachelor's degree in biochemistry from Rice University in Houston, Texas. He earned his medical degree at Vanderbilt University in Nashville, Tennessee. He trained in internal medicine at Baylor College of Medicine Affiliated Hospitals in Houston, Texas, before returning to Vanderbilt for a fellowship in hematology.

As of January 2017, Dr. Means reported the following external relationships:

Service on data and safety monitoring boards for the following company, with compensation for honoraria provided to East Tennessee State University Quillen College of Medicine:

  • Sanofi, effect of innate immunity modification by cytokines on Alzheimer's disease

Consulting on design of clinical trial for the following company, with compensation for honoraria provided to East Tennessee State University Quillen College of Medicine:

  • Xenon, trial design for hepcidin-directed therapeutics.

Work as an author or editor for following companies, with compensation as listed:

  • Lippincott Williams Wilkins/Wolters Kluwer, receiving royalties for the textbook, Wintrobe's Clinical Hematology, 12th and 13th editions.

Dr. Means serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Southern Society for Clinical Investigation, Executive Advisory Committee, compensation for lodging at annual retreat provided directly to hotel.
  • Iron Disorders Institute, Member of the Medical & Scientific Advisory Board, without compensation.

David L. Porter, MD

Dr. Porter, a board certified hematologist, is the Jodi Fisher Horowitz Professor of Leukemia Care Excellence at the Perelman School of Medicine and Abramson Cancer Center, and Director of the Blood and Marrow Transplantation and Cellular Therapeutics program at the Hospital of the University of Pennsylvania.

Dr. Porter is a member of the American Board of Internal Medicine Hematology Board Exam Committee. Additionally, he chairs or serves on numerous local, national and international committees focused on hematologic malignancies and hematopoietic stem cell transplantation. He is a member of the Board of Directors of the National Marrow Donor Program. He is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation.

Dr. Porter has authored more than 140 research articles and book chapters, is an Associate Editor for the American Journal of Hematology and has served as a manuscript reviewer for numerous medical journals, including Blood, Annals of Internal Medicine and The New England Journal of Medicine. He is annually recognized as a “Top Doc” in Philadelphia Magazine and by Castle Connolly and in 2007 was the recipient of the Leukemia & Lymphoma Society Service to Mankind Award, which is bestowed for “dedicated service to the highest standards of the medical profession, his humanistic approach to patient care and his tireless efforts in researching cures for blood cancers”.

Dr. Porter has expertise in the care of patients with hematologic malignancies including acute and chronic leukemia and in all aspects of autologous and allogeneic stem cell transplantation (SCT) and leads numerous local and national research activities. He is an accomplished clinical investigator and has published extensively in the field of stem cell transplantation and hematologic malignancies. His principal research interests are in development of novel methods of cellular therapy, stem cell transplantation and allogeneic adoptive immunotherapy.

Dr. Porter is a graduate of the University of Rochester and earned a medical degree at Brown University. He completed internship and residency at Boston University Hospital, and fellowship training at Brigham and Women's Hospital and Harvard Medical School in Boston.

As of January 2017, Dr. Porter reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Pennsylvania, from the following company:

  • Alexion, to study the use of complement inhibitor to treat graft versus host disease.

Funding for clinical trial expenses, staff, and salary support, paid to the University of Pennsylvania, from the following company:

  • Novartis, for a study of the use of CTL019 cells to treat chronic lymphocytic leukemia, acute lymphocytic leukemia, non-Hodgkin lymphoma and myeloma.

Service on data and safety monitoring boards for the following companies, with compensation as listed:

  • Center for International Blood and Marrow Research, serving as Chair of the Research in Clinical Investigation Bone Marrow Transplant data and safety monitoring board, overseeing several sponsored clinical trials, receiving honoraria.

Work as an author or editor for following companies, with compensation as listed:

  • Wiley, receiving compensation as Associate Editor of the American Journal of Hematology.

Dr. Porter holds a healthcare-related patent for CTL019 cells to treat leukemia and lymphoma, with income from Novartis paid to the University of Pennsylvania.

  • Blood and Marrow Transparent Clinical Trials Network, for project expenses, staff and salary support for numerous clinical trials, paid to the University of Pennsylvania.

Dr. Porter serves in a significant role with the following organization, receiving reimbursement or compensation as listed:

  • National Marrow Donor Program, Board of Directors, receiving reimbursement for travel expenses.